584-26-9Relevant articles and documents
Discovery of a structurally novel, drug-like and potent inhibitor of peptidylarginine deiminase
Ferretti, Patrizia,Kin Pong,Vagaska, Barbora,Merchant, Rohan,Matthews, Christopher J.,Marson, Charles M.
, p. 1109 - 1113 (2013)
The synthesis and biological properties of a structurally novel, potent and non-peptidic inhibitor of peptidylarginine deiminase are described. The novel drug-like PAD inhibitor contains a 3,5-dihydroimidazol-4-one ring that replaces the acyclic guanidine-binding unit present in arginine residues. This new drug-like PAD inhibitor was effective at 100 nM or below and could have relevance to diseases in which PAD expression is up-regulated, including rheumatoid arthritis, cancer, multiple sclerosis, and neural injury.
Benzylidene 2-aminoimidazolones derivatives: Synthesis and in vitro evaluation of anti-tumor carcinoma activity
Ling, Yong,Wang, Zhi-Qiang,Xiao, You-An,Zhu, Chenyu,Shen, Liucen,Wang, Xue-Min,Hui, Yi,Wang, Xin-Yang
, p. 1081 - 1084 (2013)
A series of benzylidene 2-aminoimidazolones derivatives were synthesized. Most compounds displayed strong inhibitory activity on the proliferation of human HepG2 cells in vitro. The active compounds were further evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay against five human cancer cell lines in vitro. Compound 2b exhibited the strongest antitumor activities with IC50 values ranging from 12.87-17.10 μM which were nearly 1-3.5 fold less than that of 5-FU (IC50=18.39-56.12 μM) in vitro. Furthermore, compound 2b could induce SMMC-7721 cell apoptosis in a dose-dependent manner. Therefore, our novel findings may provide a new framework for the design of new benzylidene 2-aminoimidazolones derivatives for the treatment of cancer.
Design and synthesis of biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety as novel antibacterial agents against Gram-positive bacteria
Wu, Yachuang,Ding, Xiudong,Xu, Sicong,Yang, Yifeng,Zhang, Xue,Wang, Chu,Lei, Hong,Zhao, Yanfang
supporting information, p. 496 - 502 (2019/01/04)
Novel biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety were designed, synthesized and evaluated for their antibacterial activity. The key compounds 7 and 9 were synthesized by the knoevenagel condensation of intermediate aldehyde 5 with rhodanine derivatives 6a?6b. The preliminary study showed that compounds 7, 9 and 10e exhibited potent antibacterial activity with MIC values of 0.125 μg/mL against S. aureus, MRSA, MSSA, LREF and VRE pathogens, using linezolid and radezolid as the positive controls. The most promising compound 10e exhibited potent antibacterial activity against tested clinical isolates of MRSA, MSSA, VRE and LREF with MIC values in the range of 0.125–0.5 μg/mL, and the potency of 10e against clinical isolates of LREF was 64-fold higher than that of linezolid. Moreover, compound 10e was non-cytotoxic with an IC50 value of 91.04 μM against HepG2 cell. Together, compound 10e might serve as a novel antibacterial agent for further investigation.
Heterocycle-containing biaryl oxazolidinone compound and preparation method thereof
-
Paragraph 0166-0168, (2019/01/08)
The invention relates to a heterocycle-containing biaryl oxazolidinone compound with the structural formula as shown in the figure I in the specification, or an optical isomer and a pharmaceutically acceptable salt and/or solvate thereof, a preparation method for the heterocycle-containing biaryl oxazolidinone compound as well as the optical isomer and the pharmaceutically acceptable salt and/or solvate thereof, and a pharmaceutical composition containing the compound. According to the heterocycle-containing biaryl oxazolidinone compound, the substituent groups R1, R2, R3, R4 and A-ring have the meanings given in the specification. The invention also relates to application of the compound as well as the pharmaceutically acceptable salt and solvate or a prodrug thereof as an antibacterial drug in treatment, especially in treatment of gram-positive bacterial infection and mycobacterium tuberculosis infection. (Please see the figure I in the specification for the structural formula of theheterocyclic ring-containing biaryl oxazolidinone compound.).
